Global Health (MEDANTA) Q2 24/25 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for Q2 and H1 ended 30 September 2024.

• Limited review reports from statutory auditors confirm no material misstatements in the results.

• Board recommended a new long-term share-based incentive plan (GHL LTIP 2024) for employees.

• Allotment of 40,000 equity shares to an employee under ESOP 2016 Scheme, increasing paid-up capital.

• Accepted resignation of a nominee director, with subsequent reconstitution of the Audit Committee.

Financial highlights

• Consolidated revenue from operations for Q2 FY25: ₹9,565.55 million, up from ₹8,504.46 million in Q2 FY24.

• Consolidated net profit for Q2 FY25: ₹1,308.44 million, up from ₹1,251.61 million in Q2 FY24.

• H1 FY25 consolidated revenue: ₹18,176.32 million, up from ₹16,300.26 million in H1 FY24.

• H1 FY25 consolidated net profit: ₹2,371.30 million, up from ₹2,271.71 million in H1 FY24.

• Basic and diluted EPS for H1 FY25: ₹8.83, compared to ₹8.46 in H1 FY24.

Outlook and guidance

• Board recommended GHL LTIP 2024 for employee retention and motivation.

• Scheme of Amalgamation with Medanta Holdings Private Limited progressing, with NCLT hearing scheduled for 20 November 2024.

• Agreement signed to operate a 750-bed hospital in Pitampura, New Delhi.